Business Wire

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001


Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell’s lead product.

This press release features multimedia. View the full release here:

Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells. NK cells are highly potent immune effectors, used alone as monotherapy, or in combination with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological malignancies and solid tumors. NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells. Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.

Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products. Cell-Easy’s facilities are located in Toulouse including state-of-the-art controlled environment suites optimized for developing manufacturing and analytical processes, proceed to environmental and material Quality Control, and execute cGMP manufacturing, fill & finish, long-term storage of Advanced Therapy Medicinal Products (ATMPs) compliant with all the requirements of regulatory standards and cGMP guidelines.

Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.

We are very pleased to collaborate with Cell-Easy on the final stages of development and GMP manufacturing of our flagship product, NK-001“, said Patrick Henno, President of Emercell.” We are looking forward to a successful and long-lasting collaboration as a key element of our development strategy. Moreover, Cell-Easy and Emercell are located in the Occitanic Region and the partnership fits perfectly with the Region’s objectives regarding the development and production of new products in the field of biotherapies, and particularly in the field of immunotherapy.

In a very competitive European landscape, we are delighted that Emercell has chosen us as their privileged CDMO Partner for their first immune-oncology approach using NK-cells”, said Guillaume Costecalde, President of Cell-Easy. “Cell-Easy CDMAO’s original approach and the team’s reactivity combined with our state-of-the-art facility allow us once again to convince ambitious ATMP developers such as Emercell to secure their development.”

About Emercell

Emercell is an oncology company developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's R&D activities are located at the IRMB (Institute of Regenerative Medicine and Biotherapies) at the Saint-Éloi University Hospital Center, Montpellier, France. Emercell's lead drug candidate, NK-001, is intended, among others, for the treatment of lymphoma patients who are refractory to conventional therapies. It is a patented process for pre-activating and amplifying allogeneic NK cells. Emercell collaborates with numerous industrial and academic partners. The company has received the support of the Occitanie Region (ADI) and Bpifrance and has obtained a FUI (financing). Emercell is a member of Eurobiomed.

About Cell-Easy

Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell and Gene modified Cell Therapy products. This integrated concept is called CDMAO. Beyond CDMO, CDMAO is not only focused on Development & Manufacturing. CDMAO is positioned as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in-depth expertise on regulatory process scale-up and analytics.

Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) both in Immuno-Oncology and Regenerative Medicine fields.

Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the healthcare of patients at the center of everything.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Media and Investor Contacts:
Emercell, Dr. Patrick Henno, President,, (+33)-6-14-77-39-21
Cell-Easy, Dr. Guillaume Lay, Business Development,, (+33)-6 15 18 13 13

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enviva Releases White Paper on the Evolution of Modern Bioenergy in Heavy Industry Verticals3.10.2022 18:00:00 CEST | Press release

Today, Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced wood biomass, published a white paper that discusses unlocking the future of biomass beyond fossil fuels into other industrial applications, including steel, cement, lime, chemicals, and sustainable aviation fuel (SAF), among others. While Enviva’s sustainably sourced biomass is predominately used today to decarbonize power and heat generation, modern biomass will increasingly be used to reduce emissions in these hard-to-abate sectors that are responsible for nearly one-third of global CO2 emissions as governments, companies, and industry endeavor to mitigate their climate change impacts through net-zero emissions goals. All sectors ‒ including energy, construction, transportation, aviation, and food systems ‒ are looking to rapidly decarbonize, and sustainably sourced biomass is the only technologically advanced, scalable, and market-ready product poised to substantially mitigate climate change and dec

DentalMonitoring Expands into Japan3.10.2022 17:53:00 CEST | Press release

New office in Tokyo; bringing smarter dentistry solutions to Japan. This press release features multimedia. View the full release here: DentalMonitoring ScanBox pro (Photo: Business Wire) DentalMonitoring, the leading global provider of smart dentistry solutions, is setting foot in Japan to serve the Asian market with its AI-powered remote monitoring solution and latest clinical data analysis platform DM Insights. Having been granted market authorization, the company headquartered in Paris, France, is now bringing its suite of intelligent solutions onto the Japanese market. From lead engagement and conversion to remote monitoring of all treatment modalities, DentalMonitoring has helped transform over 7,000 practices worldwide and over 1 million patients have already been using its ScanBoxᵖʳᵒ and 4.9 rated app, helping optimize their treatment experience. ScanBoxᵖʳᵒ will be available from Dental Monitoring Japan in October 2022.

AIT Worldwide Logistics Forms CRAF Partnership with Kalitta Air3.10.2022 17:02:00 CEST | Press release

Global supply chain solutions leader AIT Worldwide Logistics has entered into a new Civil Reserve Air Fleet (CRAF) partnership with Ypsilanti, Michigan-based Kalitta Air. The strategic alliance continues AIT’s longstanding designation as a CRAF-sponsored freight forwarder, enabling the company to continue critical supply chain support for United States Transportation Command (USTRANSCOM) missions, while also increasing access to global routes, capacity, and charters for customers. This press release features multimedia. View the full release here: AIT Worldwide Logistics forms CRAF partnership with Kalitta Air (Photo: Business Wire) “For more than 10 years, we’ve been proud and always at the ready to support USTRANSCOM through the CRAF program,” said AIT’s Chief Business Officer, Greg Weigel. “As AIT continues to grow our global footprint and scope, securing a CRAF partnership with an airline that has similar global reach, with

Survey Reveals Tech Trust Gap Amongst UK Bank Customers3.10.2022 15:38:00 CEST | Press release

New research by Mitek, a global leader in digital identity and digital fraud prevention, and YouGov has found that banking customers’ trust in technology remains low in the United Kingdom. Only half (52%) of UK bank customers feel that technology like artificial intelligence (AI) and biometrics positively impacts their trust in banks, and only 5% would prefer all interactions with AI/automated systems when engaging banks. These findings are based on a survey of more than 2,200 adults across age groups and UK regions. The industry has undergone a rapid digital transformation in the last few years, with Gartner predicting IT spending by banking and investment services firms growing by 6.1% by end of 2022, to US$623 billion worldwide. While nearly eight in 10 (79%) customers are satisfied with their bank’s digital experience (rating it “good”, “very good”, “or “excellent”), banks are in danger of facing a market-driven stalemate in their research and development should the tech trust gap

Bacardi Announces Leadership Moves to Drive Future Growth3.10.2022 15:30:00 CEST | Press release

Bacardi Limited, the largest privately held spirits company in the world, today announces a series of C-suite talent moves within global commercial and finance and the North America business. This press release features multimedia. View the full release here: Pete Carr to become Bacardi Executive Vice President and Global Growth Officer (Photo: Business Wire) CurrentRegional President for North America Pete Carr will take on the newly created role of Executive Vice President and Global Growth Officer. Pete will be responsible for commercial excellence and strategy, route-to-market models, digital commerce, and on-trade relationships for the family-owned spirits business. Pete comes armed to spearhead continued commercial success for Bacardi, with a lifetime of spirits experience and more than eight years at the helm of one of the company’s largest markets. Pete has showcased fearlessness and a founder’s mentality throughout his

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom